Clinical Trials Sponsored by Vinnova

Total 240 results

Halmstad University
Vinnova

Completed

A Mobile App for Medication Adherence in Persons With Hypertension: a Pilot Study

Hypertension

Sweden
Attgeno AB
Vinnova

Withdrawn

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

COVID-19 | Pulmonary Hypertension

Sweden
Xintela AB
Vinnova

Recruiting

A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers

Venous Leg Ulcer

Sweden
Region Skane
Vinnova

Completed

PHMB-based Antiseptic Use in Full-thickness Surgical Wounds

Surgical Site Infections

Sweden
Lund University
Vinnova

Completed

An Antiinflammatory Diet as Modulator of Cardiometabolic Risk and Body Weight in Healthy Subjects

Overweight | Metabolic Syndrome | Insulin Resistance

Sweden
Mälardalen University
Danderyd Hospital; Vinnova

Completed

Mental Imagery Neurofeedback in Strokerehabilitation

Stroke | Hemiparesis

Sweden
Region Skane
Vinnova; Bactiguard AB

Completed

Biofilm Formation on Different Endotracheal Tube Materials

Respiratory Insufficiency | Ventilator-associated Pneumonia

Sweden
Isifer AB
Ferring Pharmaceuticals; Vinnova

Unknown

A Study of Lidocaine Pertubation as a Treatment for Unexplained Infertility

Unexplained Infertility

Poland
Innova Vascular, Inc.

Not yet recruiting

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST) (TRUST)

Pulmonary Embolism
Lund University
Vinnova; Öste Venture AB

Completed

Dietary Fibre and Metabolic Benefits

Glucose Tolerance

Sweden
Göteborg University
Vastra Gotaland Region; Vinnova

Completed

The Effect of Probiotic Streptococci and pH-rising Components on the Oral Microbial Flora

Hyposalivation

Sweden
Bio-innova Co., Ltd

Not yet recruiting

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
VitNovo, Inc.

Completed

DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients

Type2 Diabetes

Taiwan
Bio-innova Co., Ltd

Not yet recruiting

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg

Healthy Subjects
Bio-innova Co., Ltd

Recruiting

Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®

Healthy Subjects

Thailand
Bio-innova Co., Ltd

Not yet recruiting

Desogestrel Tablets (0.075 mg) Relative to Originator Desogestrel Tablets (0.075 mg)

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Healthy Subjects
Lund University
Vinnova; Anti-Diabetic Food Centre

Completed

Impact of Meal Order on Postprandial Cardiometabolic Risk Markers

Glucose Metabolism Disorders | Metabolic Diseases | Insulin Resistance | Hyperinsulinism | Metabolic Syndrome X

Sweden
Bio-innova Co., Ltd

Not yet recruiting

Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg (DAP-030-23)

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg (TIC-025-23)

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator

Healthy Subjects
Lund University
Vinnova; Antidiabetic Food Centre AFC

Completed

Effects of Functional Ingredients in an Acute Metabolic Challenge Context

Metabolic Syndrome

Sweden
Karolinska University Hospital
Region Stockholm; Vinnova; Eurostars

Active, not recruiting

Dysautonomia and Systemic Interactions in Traumatic Brain Injury (DYSI-TBI)

Traumatic Brain Injury | Dysautonomia | Inflammation, Brain | Sympathetic; Imbalance

Sweden
Venova Medical

Recruiting

Early Feasibility of the Velocity™ Percutaneous pAVF System (VENOS-1)

Arteriovenous Fistula

Paraguay
InnoRa GmbH

Terminated

Safety and Tolerance of the Use of InnoCath AB® Hyper-compliant Balloon (HYPER)

Lesions in the Superficial Femoral Artery and/or Popliteal Artery Pars I/II

Germany
InnoRa GmbH

Completed

Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon

Coronary Restenosis

Switzerland, Germany
InnoRa GmbH

Completed

Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon (FIMLIMUSDCB)

DES In-stent Stenosis

Malaysia
Vastra Gotaland Region
Sahlgrenska University Hospital, Sweden; Vinnova

Active, not recruiting

Influence on Cough and Airway Symptoms by Oral Capsaicin

Cough

Sweden
InnoRa GmbH

Completed

Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter Malaysia (SCBDNMAL)

Coronary Artery Disease

Malaysia
InnoRa GmbH

Completed

Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter (SCBDENOVO)

Coronary Artery Disease

Switzerland, Germany
Lund University
Skane University Hospital; Vinnova; Carbiotix AB

Active, not recruiting

Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes

Diabetes Type 2

Sweden
Hinova Pharmaceuticals Aus Pty Ltd

Completed

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Australia
Hinova Pharmaceuticals Inc.

Completed

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Metastatic Castration Resistant Prostate Cancer

China
Hinova Pharmaceuticals Inc.

Completed

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Metastatic Castration Resistant Prostate Cancer

China
Region Skane
Lund University; Vinnova; Innovation Skåne AB/ Sweden

Completed

Evaluation of a Novel Medical Device to Facilitate Gel Instillation During Change of Long-term Urinary Catheters

Anesthesia, Local | Incontinence, Urinary | Urinary Catheters | Retention, Urinary

Sweden
BioNova Pharmaceuticals (Shanghai) LTD.

Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

AML, Adult | ALL, Adult

China
Hospital Arnau de Vilanova

Completed

Effectiveness of Cyanoacrylate Glue in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients: Randomised Clinical Trial (CIANO-ETI) (CIANO-ETI)

Randomized Controlled Trial | Catheterization, Peripheral | Nursing Care | Vascular Access Device

Spain
Hospital Arnau de Vilanova

Unknown

Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Carcinoma, Non-Small-Cell Lung

Spain
Innovo Therapeutics, Inc.

Recruiting

Ointment to Prevent Scar After Thyroidectomy

Scar

Korea, Republic of
Hinova Pharmaceuticals Inc.

Recruiting

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

mCRPC

China
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Hinova Pharmaceuticals Inc.

Recruiting

A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Metastatic Castration-resistant Prostate Cancer

China

3

Subscribe